Compounds > 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone
Page last updated: 2024-11-03

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Leukemia, Promyelocytic, Acute

4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone has been researched along with Leukemia, Promyelocytic, Acute in 1 studies

4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.

Leukemia, Promyelocytic, Acute: An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bang, BE1
Ericsen, C1
Aarbakke, J1

Other Studies

1 other study available for 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Leukemia, Promyelocytic, Acute

ArticleYear
Effects of cAMP and cGMP elevating agents on HL-60 cell differentiation.
    Pharmacology & toxicology, 1994, Volume: 75, Issue:2

    Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Cell Differentiation; Cell Division; Cyclic AMP; Cyc

1994